|
|
| home about us advertise with us downloads links privacy contact us site map copyright policy |
| ||
Bowel Function and Nutritional InfluencesTel: +44 (0)20 8445 4550 The author of this article cannot be held responsible for individual medical problems associated with bowel dysfunction and the recommendations made must be approved by patients' medical advisors. Hippocrates, the father of modern medicine, made the famous recommendation: "Make food your medicine". In the case of bowel function, this could indeed be helpful! If there is any pain and distension accompanying lack of bowel movement, this may signify bowel obstruction, which needs medical intervention. This may be caused by reaction to drugs, Inflammatory Bowel Disease, the Irritable Bowel Syndrome, parasites, bowel cancer or other diseases. Apple pectin slows down the transit time of food in the bowel. are helpful in regulating bowel function and constipation. It is hoped that eventually a rhythm for bowel emptying will establish itself5.TABLE OF CONTENTS TAB 1: GENERAL INFORMATION Symposium Agenda - Day 1 Symposium Agenda - Day 2 List of Contributors Faculty Roster Differences in Irritable Bowel Syndrome LECTURE 2: Differences in Irritable Bowel Syndrome PP Tegaserod referencesTegaserod (Zelnorm® -- Novartis) References 1. Viera A, Hoag S, Shaughnessy J. Management of irritable bowel syndrome. Evidence-based positions statement on the management of irritable bowel syndrome in North America. Camilleri M. Management of the irritable bowel syndrome. Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. Muller-Lissner A, Fumagalli I, Bardhan KD, Pace F, Pecher E. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Tougas G, Snape WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation predominant irritable bowel syndrome.Title: Psychophysiology of Irritable Bowel Syndrome (IBS) SSW Investigator: Rona Levy PI SSW Predoctoral Research Assistant: Michelle Garner Description The aim of the study is to determine whether IBS is uniquely associated with specific comorbid conditions, which would suggest shared pathophysiology, or whether comorbidity is an expression of psychological contributions to the etiology of IBS. Funding Sources: National Institute of Diabetes & Digestive & Kidney Diseases Start/End Dates: December 2002 through November 2007 Naltrexone in the treatment of alcohol dependence. The temporal relationship, the doses of the drug used and the clinical syndrome would probably suggest that our patient had an idiosyncratic reaction. Sulesomab is safer and easier to use than radiolabelled white blood cells, so it is being studied in other conditions, such as inflammatory bowel disease, where the detection of inflammation is important. Approved indication: irritable bowel syndrome in women Australian Medicines Handbook Section 12.2.1 The cause of irritable bowel syndrome is uncertain. Tegaserod may therefore have a role in patients with irritable bowel syndrome who are predominantly troubled by constipation. A double-blind trial randomised 881 patients with constipation-predominant irritable bowel syndrome to take tegaserod or a placebo for 12 weeks. Tegaserod produced statistically significant subjective improvements in bowel movements and abdominal discomfort. There is a large placebo response in patients doi:10.1053/j.gastro.2004.03.013Our aim was to test whether enteric 5-HT signaling is defective in these disorders. IBS-D. When 5-HT release was investigated under basal and mechanical stimulation conditions, no changes were detected in any of the groups relative to controls. Conclusions: These data show that UC and IBS are as-sociated with similar molecular changes in serotonergic signaling mechanisms. While UC and IBS have distinct pathophysiologic properties, these data suggest that shared defects in 5-HT signaling may underlie the al-tered motility, secretion, and sensation. These findings represent the first demonstration of significant molecu-lar alterations specific to the gut in patients with IBS and support the assertion that disordered gastrointestinal function in IBS involves changes intrinsic to the bowel. thermore, studies of the numbers of EC cells and the mucosal content of 5-HT suggest that 5-HT availability may be altered in IBS and inflammatory bowel dis-ease.8 -13 A common molecular mechanismcvfunctions in health VSL #1 Effects of VSL#3 on symptoms and GI transit in patients with $144,700 diarrhea-predominant irritable bowel syndrome Janssen #33 Genetic epidemiology and pathophysiological mechanisms of $ 120,000 functional dyspepsia Proctor and Gamble Effect of locally-delivered bisacodyl Alizyme ATL#4 Effects of renzapride on GI transit in constipation-predominant $ 310,633 (1A4299) irritable bowel syndrome GlaxoSmithKline Effects of an NK3 antagonist, SB-223412, on rectal sensorimotor $ 309,531 Function in health Novartis Effects of a 5HT-4 receptor partial agonist, tegaserod, on postprandial $ 173,030 gastric function Forest Effects of dexloxiglumide on small bowel and colonic transit in female $ 227,676 constipation-predominant or alternating irritable bowel syndrome Michael Camilleri, M.D. -7- VSL Effects of VSL#3 on symptoms and colonic transit in patients with $ 134,489 abdominal bloating with irritable bowel syndrome Adolor Effect of alvimopan, a mu-opioidDecember 2002;18(3)-PharmaNoteAlthough the exact pathophysiology is un-known, postulated mechanisms include: GI tract dysmotility, psychological disturbances, inflamma-tory processes, and altered visceral sensitivity. Also, there is mounting evidence that IBS can oc-cur after a patient has had infectious gastroenteritis. It is thought that up to 25% of those admitted for such diagnosis develop IBS-like symptoms.4 IBS as a function of a neurological bowel disease has re-cently come to the forefront of research. Current pharmacotherapeutic modalities of therapy for IBS include fiber intake of 25-30g/day and mild osmotic laxatives for constipation predominant; an-ticholinergics, opioids including loperamide for di-arrhea predominant; and antidepressants or anti-spasmodics to treat the pain associated with IBS. Although these treatments are effective in the ma-jority of patients, there remains a small subgroup of patients that fail to respond to these therapeutic in-terventions. Alosetron is available as a 1Print WH_ColonHealth23This is intended as an information resource providing guidelines for women. As always, check with your own healthcare practitioner with your specific concerns and questions. Menopause and Colon Health I often get questions from patients about their bowel symptoms. Although typically a syndrome that starts early in life (teens and young adult-hood), it follows women throughout their years. Many women are familiar with bowel changes that occur just before or during their periods. Although menopause may change bowel habits, remember that these are also the same years when more serious problems, such as colon cancer, can occur. Women cannot be as cavalier about changes in bowel habits at age 50 as you can at age 20. Remember to have routine colon cancer screening and investigate new changes in your bowel function.Sem título de diapositivoIrritable bowel syndrome (IBS) is a functional intestinal disorder which is characterised by regular intestinal pain and discomfort. The etiology of IBS is unclear but a disturbance in the composition of intestinal microbiota has been suggested. There are indications that probiotic therapy may be useful in the alleviation of IBS symptoms. In the present study the faecal microbiota of IBS subjects was compared to that of the controls. The aim was to study whether the prevalence or level of some specific microbial groups correlate with IBS. Also the stability of dominant faecal bacterial groups was investigated. 26 subjects (19 F, 7 M, age 20-65 yrs; mean 46) filling the Rome criteria were included in the IBS group and 25 subjects in the control group (18 F, 7 M, age 23-63 yrs; mean 43). Faecal samples were processed in an anaerobic chamber within 1-5 hours after defecation. Faecal samples were obtained on three separate occasions (0, 3 and 6 months) from 21 IBS and 18 controlSymptoms arising in functional gastrointestinal disorders, including the irritable bowel syn-drome, are currently considered to result from sensory-reflex disturbances in the gut (1). This neurophysiologic concept admits that all functional disorders have a common pathophysiologic mechanism, and that specific clinical syndromes depend on the sensory and reflex pathways in-volved. The goal to be reached with provocation testing is a mechanistic diagnosis iden-tifying the sensory-reflex disturbance responsible for symptoms, which may include rectal hypersensitivity in patients with irritable bowel syndrome (3,4). Izquierdo et al. have shown how the identification of rectal hypersensitivity may influence the behavior of patients with irritable bowel syndrome in the long run, thus decreasing the demand for healthcare resources, particularly medical consultations (5). In patients with irritable bowel syndrome these changes only become apparent when distension stimulates DIAGNOSTIC GUIDEAntidepressants are used to manage a variety of symptoms and syndromes other than psychiatric disorders. They are particularly useful in controlling functional symptoms, i.e., those with no definable pathological explanation.1, 2 Examples include irritable bowel syndrome, functional dyspepsia, and fibromyalgia. Antidepressants also are used to manage chronic pain syndromes, whether the pain is of unexplained origin or related to a defined medical condition. These agents have an important role in migraine prophylaxis and also have been used to suppress unexplained nausea and vomiting associated with functional gastrointestinal conditions.3 Consequently, it is not surprising that antidepressants have been offered to patients with Cyclic Vomiting Syndrome (CVS), and fortunately they have proven In CVS, clinical experience has been restricted almost exclusively to the TCAs.6, 7 No single TCA has surfaced as superior to the other for the syndrome, although amitriptyline is mostPR Zelmac 13.02.04Basel, 13 February 2004 - Zelmac® (tegaserod), a new treatment for irritable bowel syndrome (IBS) provides patients satisfying overall relief of symptoms, including abdominal pain and discomfort, bloating and constipation, according to a new study just published in the Scandinavian Journal of Gastroenterology. IBS is characterized by abdominal pain/discomfort, bloating, and altered bowel function (constipation and/or diarrhea).3,4,5 Until recently, the cause of IBS has been poorly understood and under-appreciated. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. Final version-March 19, 2003 3 Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. NJ. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Functional bowel disorders and functional abdominal pain. The role of serotoninFactsheet 13 copyIn the normal course of digestion, people produce an estimated two litres of wind in the bowel every day - equivalent to a large lemon-ade bottle! It has to go somewhere and, when the bowel is function-ing normally, most of this is absorbed or passes upwards or downwards, occasionally with some embarrassment in social situa-tions. Bloating and flatulence are common symptoms in Irritable Bowel Syndrome (IBS). It is however clear that there exists a problem both with the movement of the bowel and its sensitivity. The bowel is also an emotional organ. The English language is littered with expressions of bowel disorders relating to stressful events - "butterflies in the stomach", "gut reaction", "knotted stomach" and even "sick as a parrot" are phrases we all recognise. Patients taking laxative medicines to provide bulk in the bowel, such as Fybogel or Lactulose, often complain of increased wind production. Finally, regular exercise helps many people to main-tain aPowerPoint PresentationOverview of R&D Pipeline May 18, 2005 Masao Shimizu Senior Corporate Officer Senior Vice President, Development Astellas Pharma Inc. Cautionary statement regarding forward-looking information Lower urinary tract syndrome Diabetic nephropathy Chronic hepatitis C virus infection (Advaferon for use in combination with ribavirin) Irritable bowel syndrome (IBS) Type II diabetes (Concomitant treatment with Biganides) Type II diabetes (Concomitant treatment with insulin sensitizers) Post surgical pain, post traumatic pain, Prevention of deep vein thrombosis (DVT), Prevention of thromboembolism in atrial fibrillation Irritable bowel syndrome (IBS) Functional symptoms with benign prostatic hyperplasia Rheumatoid arthritis Suppression of organ rejection in liver and kidney transplants Asthma Classification Beta 3 receptor agonistWalker Article for ReprintEnthusiastic expressions of approval for colon hydrotherapy are undeniable medical endorsements for this significant complementary treatment which removes metabolic waste from a person's large bowel without applying toxic agents of any kind. He never had a bowel movement for a week at a time. The beneficial effect was dramatic, for within six months he was experiencing a natural and normal bowel movement every day. "Colon hydrotherapy is the perfect specific procedure to eliminate constipation and restore normal bowel function. It turns out that she had irritable bowel syndrome complicated by candidiasis. She has good bowel movements twice daily with no gas. It's better than an enema, which is merely a lower bowel cleanse, as opposed to a colonic which is a thorough cleanse of the entire bowel. It's similar to comparing the diagnostic efficacy of a sigmoidoscopy of the short end of the bowel to a colonoscopy which takes in the whole bowel.1 | 2 | 3
| 4 | 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 14 | 15 | | ||
